Minimally differentiated acute myeloid leukemia (MO).

被引:0
作者
Frenkel, MA [1 ]
Tupitsyn, NN [1 ]
Volkova, MA [1 ]
Fleischman, EW [1 ]
机构
[1] NN Blokhin Oncol Res Ctr, Moscow, Russia
来源
GEMATOLOGIYA I TRANSFUZIOLOGIYA | 1998年 / 43卷 / 04期
关键词
acute myeloid leukemia; bone marrow; dysplasia; blast cells; cytochemical markers; karyotype;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Morphologic, cytochemical, immunophenotypic and cytogenetic features of AML-MO blasts and their proliferation in a soft agar cultures were studied in 18 patients. To evaluate the role of the modern techniques in differentiation of ANLL FAB types, the following patient groups were compared: AML-MO (18 cases), AML M1 (41 cases), AML M6 (25 cases) and MDS RAEB-T (3 cases). Populations of the bone marrow nonblastic cells were compared in AML MO and AML M1 to detect the presence of myelodysplastic features. AML MO showed remarkable heterogeneity of morphologic, cytochemical, immunophenotypic and cytogenetic patterns of the blast cells. These cells are not able to proliferate in agar cultures. Prognostically unfavorable karyotype changes (including rearrangements of 3q21/q26, -5/5q-, -7/7q- and complex chromosome abnormalities) were more often observed in AML MO than AML M1 and AML M2. The difference was statistically significant, Isolated bone marrow dysplasia of granulocytic or erythroid cells and twolineage dysplasia in AML MO was recorded three times more frequently than in AML M1. Trilineage bone marrow dysplasia was revealed in AML MO only. MO blast cells were associated not only with AML but also with CML BC (34%) and MDS RAEB-T (12.5%). The recognition of AML MO is essential for a complete cytologic classification of AML. All AF cases must be examined with large panel of cytochemical markers including MPO, SBB, granulocytic esterase. In addition, immunophenotyping must be performed.
引用
收藏
页码:9 / 13
页数:5
相关论文
共 50 条
  • [21] Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance
    Van Thanh Hoang
    Zepeda-Moreno, Abraham
    Ho, Anthony D.
    BIOTECHNOLOGY JOURNAL, 2012, 7 (06) : 779 - 788
  • [22] Metabolomics in acute myeloid leukemia
    Wojcicki, Anna V.
    Kasowski, Maya M.
    Sakamoto, Kathleen M.
    Lacayo, Norman
    MOLECULAR GENETICS AND METABOLISM, 2020, 130 (04) : 230 - 238
  • [23] Immunotherapy in acute myeloid leukemia
    Arpinati, Mario
    Curti, Antonio
    IMMUNOTHERAPY, 2014, 6 (01) : 95 - 106
  • [24] Classification of acute myeloid leukemia
    Hwang, Sang Mee
    BLOOD RESEARCH, 2020, 55 : 1 - 4
  • [25] Venetoclax in Acute Myeloid Leukemia
    Mihaila, Romeo G.
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2023, 18 (01) : 11 - 28
  • [26] Pharmacogenomics in acute myeloid leukemia
    Roumier, Christophe
    Cheok, Meyling H.
    PHARMACOGENOMICS, 2009, 10 (11) : 1839 - 1851
  • [27] Immunotherapy in Acute Myeloid Leukemia
    Grosso, Dolores A.
    Hess, Rosemary C.
    Weiss, Mark A.
    CANCER, 2015, 121 (16) : 2689 - 2704
  • [28] Pathobiology of acute myeloid leukemia
    Christ, Oliver
    Feuring-Buske, Michaela
    Hiddemann, Wolfgang
    Buske, Christian
    MEDIZINISCHE KLINIK, 2007, 102 (04) : 290 - 295
  • [29] Decitabine for acute myeloid leukemia
    Marks, Peter W.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (03) : 299 - 305
  • [30] Genomics of Acute Myeloid Leukemia
    Graubert, Timothy A.
    Mardis, Elaine R.
    CANCER JOURNAL, 2011, 17 (06) : 487 - 491